Viatris (VTRS) Cash from Investing Activities (2019 - 2026)

Viatris' (VTRS) quarterly Cash from Investing Activities came in at $277.4 million in Q1 2026, up 526.11% year-on-year from $44.3 million in Q1 2025, and up 231.34% quarter-over-quarter from -$211.2 million in Q4 2025.

Viatris (VTRS) Cash from Investing Activities (2019 - 2026) Analysis & Trends

Viatris' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $277.4 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 526.11% year-over-year to $277.4 million in Q1 2026; TTM through Mar 2026 was -$85.2 million, a 104.51% decrease from a year earlier, with the FY2025 full-year figure at -$427.7 million, down 123.75% from the prior year.
  • Cash from Investing Activities improved to $277.4 million in Q1 2026 per VTRS's latest filing, from -$211.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $1.7 billion in Q3 2024 and bottomed at -$749.5 million in Q1 2023.
  • The 5-year median for Cash from Investing Activities is -$66.9 million (2022), against an average of $132.9 million.
  • Across the five-year window, Cash from Investing Activities sank 1020.33% in 2023 and surged 3283.79% in 2024, its largest moves.
  • Year by year, Cash from Investing Activities stood at $1.7 billion in 2022, then tumbled by 98.46% to $26.7 million in 2023, then sank by 731.84% to -$168.7 million in 2024, then fell by 25.19% to -$211.2 million in 2025, then surged by 231.34% to $277.4 million in 2026.
  • Per Business Quant, the three latest VTRS Cash from Investing Activities figures stand at $277.4 million (Q1 2026), -$211.2 million (Q4 2025), and -$98.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 89.60 Bn 87.73 Bn - -
2 Teva Pharmaceutical Industries 35.90 Bn 32.16 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.49 Bn 30.55 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.56 Bn 23.49 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 23.13 Bn 20.97 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 21.80 Bn 21.80 Bn - -
7 Viatris 20.28 Bn 18.48 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.75 Bn 16.43 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.61 Bn 12.18 Bn 785.00 Mn -60.00 Mn
10 Vireo Growth 10.52 Bn 10.37 Bn 59.30 Mn 8.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 277.40 Mn
Mar 31, 2026 277.40 Mn
Dec 31, 2025 -211.20 Mn
Dec 31, 2025 -211.20 Mn
Sep 30, 2025 -98.90 Mn
Sep 30, 2025 -98.90 Mn
Jun 30, 2025 -52.50 Mn
Jun 30, 2025 -52.50 Mn
Mar 31, 2025 -65.10 Mn
Mar 31, 2025 -65.10 Mn
Dec 31, 2024 -168.70 Mn
Dec 31, 2024 -168.70 Mn
Sep 30, 2024 1.75 Bn
Sep 30, 2024 1.75 Bn
Jun 30, 2024 375.80 Mn
Jun 30, 2024 375.80 Mn
Mar 31, 2024 -154.30 Mn
Mar 31, 2024 -154.30 Mn
Dec 31, 2023 26.70 Mn
Dec 31, 2023 26.70 Mn